<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696173</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-605</org_study_id>
    <nct_id>NCT03696173</nct_id>
  </id_info>
  <brief_title>Safety Study of Abatacept in Rheumatoid Arthritis Participants</brief_title>
  <official_title>Comparative Safety of Biologic Disease-modifying Treatment Initiation With Abatacept in Rheumatoid Arthritis: A Real-world Population-based Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A observational study to assess whether biologic disease-modifying (BDM) treatment initiation
      with abatacept for rheumatoid arthritis is associated with an increased risk of serious
      infection and cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2015</start_date>
  <completion_date type="Actual">June 29, 2018</completion_date>
  <primary_completion_date type="Actual">June 29, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of increased risk of serious infection while taking abatacept</measure>
    <time_frame>Approximately 7 years</time_frame>
    <description>With methotrexate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of malignancy while taking abatacept</measure>
    <time_frame>Approximately 7 years</time_frame>
    <description>With methotrexate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of increased risk of serious infection while taking abatacept</measure>
    <time_frame>Approximately 7 years</time_frame>
    <description>Without methotrexate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of malignancy while taking abatacept</measure>
    <time_frame>Approximately 7 years</time_frame>
    <description>Without methotrexate</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5800</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Participants taking abatacept</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants taking abatacept with methotrexate</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Participants taking abatacept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>Participants taking abatacept with methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatoid arthritis (RA) participant, population-based cohort study approach within the
        US-based Truven MarketScan population and Supplemental US Medicare database
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient initiates BDM treatment with at least one claim for the treatment. Patients
             will be presumed to be new users of a treatment if there is no claim for the drug or
             any other BDM in the 180 days prior to the cohort entry date

          -  Patient has at least two diagnoses for RA in the patient's history prior to and
             including the entry date or within the 180 days after the entry date

          -  Patient is aged 18 years or older on the entry date

          -  Patient was enrolled in the database for at least 180 days before the entry date

        Exclusion Criteria:

          -  Patient is younger than 18 years on the entry date

          -  Patients who receive abatacept and another biologic simultaneously

          -  Patients who have an outcome diagnosis in the baseline period will be excluded from
             the cohort analyses for that outcome

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>October 3, 2018</last_update_submitted>
  <last_update_submitted_qc>October 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

